SEC Form 4 · accession 0000899243-16-017490

Larimar Therapeutics, Inc. · LRMR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Apr 1, 2016

Accepted (ET)

Apr 4, 2016 · 9:00 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001374690

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Apr 1, 2016	D	4,424	$7.91	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F1,F2	$7.91	Apr 1, 2016	A	6,100	A	—	Apr 1, 2026	Common Stock	6,100	6,100	D

F1In a Form 4 filed on January 27, 2016, a grant of 4,424 shares of common stock on January 25, 2016 (the "Original Grant") was reported on behalf of the Reporting Person in lieu of cash fees under the Non-Employee Director Compensation Policy (the "Policy") pursuant to a Restricted Stock Agreement at a price equal to $7.91 per share, the market price of the stock on the grant date (the "Original Price"), subject to vest over a period of one year starting January 1, 2016 on a quarterly basis in arrears. It was recently determined that the Original Grant was made owing to an administrative error, since the Reporting Person requested a stock option in lieu of cash fees under the Policy.
F2(Continued from Footnote 1) To correct the error, the Company canceled the Original Grant on April 1, 2016 and granted a stock option (the "Replacement Option") to the Reporting Person in lieu of cash fees under the Policy pursuant to a Non-Qualified Stock Option Agreement at an exercise price equal to the Original Price, subject to vest over a period of one year starting January 1, 2016 on a quarterly basis in arrears. The correction is reported in this Form 4 as a cancellation of the Original Grant and the grant of the Replacement Option.